An update: Health economics of managing multiple myeloma

European Journal of Cancer

Volumn 42, Issue 11, 2006, Pages 1684-1691

  Moeremans, K ^a   Annemans, L ^a,b  

^a HEDM   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Bortezomib; Cost; Drug therapy; Economics; Multiple myeloma; Pharmacoeconomics; Review; Stem cell transplantation; Thalidomide

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; BUSULFAN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; IMMUNOMODULATING AGENT; INTERFERON; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; FRACTURE; HEALTH ECONOMICS; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; MULTIPLE MYELOMA; NEUTROPENIA; PATIENT CARE; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RECURRENT CANCER; RISK ASSESSMENT; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA;

EID: 33746500207     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.036     Document Type: Article

References (34)

1. Wisloff F., Gulbrandsen N., and Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 16 4 (1999) 329-341
2. Reed S.D., Radeva J.I., Glendenning G.A., Coleman R.E., and Schulman K.A. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol 28 1 (2005) 8-16
3. Richardson P.G., Sonneveld P., Schuster M.W., et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
4. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood, 2005; (First Edition Paper, prepublished ahead of print, August 2005).
5. Rajkumar S.V., and Kyle R.A. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80 10 (2005) 1371-1382
6. Dispenzieri A. Bortezomib for myeloma-much ado about something. N Engl J Med 352 24 (2005) 2546-2548
7. van Agthoven M., Segeren C.M., Buijt I., et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 40 8 (2004) 1159-1169
8. Engelhardt M., Winkler J., Waller C., et al. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumour and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplant 19 (1997) 529-537
9. Engelhardt M., Bertz H., Wasch R., and Finke J. Analysis of stem cell apheresis products using intermediate-dose filgastrim plus large volume apheresis for allogeneic transplantation. Ann Hematol 80 (2001) 201-208
10. Engelhardt M., Bertz H., Afting M., Waller C.F., and Finke J. High-versus standard dose filgastrim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 17 (1990) 2160-2172
11. Coutet J., Limat S., Voillat L., Deconinck E., Cahn J., and Woronoff-Lemsi M.C. Economic impact of outpatient chemotherapy in multiple myeloma. Bull Cancer 91 9 (2004) 729-734
12. Denz U, Haas P, Wäsch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspective. Eur J Cancer, current issue.
13. Levy V., Katsahian S., Fermand J.P., Mary J.Y., and Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine 84 4 (2005) 250-260
14. Ruiz-Arguelles G.J., Gomez-Rangel D., Ruiz-Delgado G.J., Ruiz-Arguelles A., Perez-Romano B., and Rivadeneyra L. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol 110 4 (2003) 179-183
15. Bargetzi M.J., Passweg J., Baertschi E., et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 31 2 (2003) 99-103
16. Mishra V., Andresen S., Brinch L., et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 35 12 (2005) 1149-1153
17. Mishra V., Vaaler S., and Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol 25 3 (2003) 179-184
18. Kouroukis C.T., O'Brien B.J., Benger A., et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma 44 1 (2003) 29-237
19. Bergsagel P.L. Chemotherapy of multiple myeloma: Melphalan-40 years old and still going strong. Biol Blood Marrow Transplant 9 (2003) 2-3
20. Gulbrandsen N., Wisloff F., Nord E., Lenhoff S., Hjorth M., Westin J., and Nordic Myeloma Study Group. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 66 5 (2001) 328-336
21. Stolk E.A., and Poley M.J. Criteria for determining a basic health services package. Recent developments in The Netherlands. Eur J Health Econ 6 1 (2005) 2-7
22. Sculpher M., and Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty-when is there sufficient evidence?. Value Health 8 4 (2005) 433-446
23. Zeiser R, Finke J. Allogeneic hematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
24. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21 8 (2003) 1480-1484
25. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113 4 (2001) 1020-1034
26. Body J.J. Effectiveness and cost of biphosphonate therapy in tumour bone disease. Cancer 97 3 Suppl (2003) 859-865
27. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of biphosphonates in multiple myeloma. J Clin Oncol 20 17 (2002) 3719-3736
28. Jantunen E. Biphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol 71 3 (2003) 231-232
29. Sezer O., Jakob C., Zavrski I., Heider U., Fleissner C., and Freund M. Biphosphonates in early myeloma. Eur J Haematol 71 (2003) 231-232
30. Coyte P.C., Dobrow M.J., and Broadfield L. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics 19 8 (2001) 845-854
31. Bruce N.J., McCloskey E.V., Kanis J.A., and Guest J.F. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 104 (1999) 358-364
32. Anonymous. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks. Prescrire Int 14 77 (2005) 94-98
33. Mehta J., Duff S.B., and Gupta S. Cost-effectiveness of Bortezomib in the treatment of advanced multiple myeloma. Manag Care Interface 17 9 (2004) 52-61
34. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 1 (2005) 35-39